TST: Skeletonised Versus Pedicled Internal Thoracic Artery

Sponsor
Lars Peter Riber (Other)
Overall Status
Completed
CT.gov ID
NCT05562908
Collaborator
Odense Patient Data Explorative Network (Other), GCP-unit at Odense University Hospital (Other)
165
1
3
32
5.2

Study Details

Study Description

Brief Summary

It is to date unknown whether Thunderbeat has a place in harvesting the left internal mammary artery (LIMA) and whether skeletonisation is superior to pedicle harvested LIMA. Though, some studies have shown improved flow-rates in the skeletonised graft while others shows compromised blood flow to the thoracic wall after pedicle harvested LIMA.

The purpose of this study is to improve the quality of life for patients undergoing coronary artery bypass graft (CABG) operations.

The aim of this study is to compare three groups of LIMA harvesting techniques: Pedicled, surgical skeletonised and skeletonised with Thunderbeat to determine the best way to harvest LIMA during CABG operations.

The study design is an experimental randomized controlled trial in a single centre.

Study population: Adult patients enlisted for elective stand-alone CABG surgery at the Department of Cardiothoracic surgery, Odense University Hospital.

Study Unit: Test-days within subject and subject

The study will address two main hypotheses in CABG patients:
  1. That both the surgical skeletonised and Thunderbeat skeletonised harvesting techniques of LIMA are superior to pedicled harvesting in regards to flowrates and pulsatility index (PI).

  2. Skeletonized harvesting of LIMA graft compared to pedicled harvesting improves patient quality of life three days, 30 days, and six months postoperatively.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Pedicled
  • Procedure: Surgical skeletonised
  • Procedure: Thunderbeat skeletonised
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
165 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Randomised trialRandomised trial
Masking:
Double (Investigator, Outcomes Assessor)
Masking Description:
After randomisation, the attending consultant informed the patient of the harvesting method. Data collector and outcome adjudicator were blinded.
Primary Purpose:
Treatment
Official Title:
Skeletonised Versus Pedicled Internal Thoracic Artery - A Randomised Study
Actual Study Start Date :
Apr 1, 2019
Actual Primary Completion Date :
Apr 30, 2021
Actual Study Completion Date :
Nov 30, 2021

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Pedicled

Harvesting of LIMA with its surrounding tissue: fascia, veins, etc

Procedure: Pedicled
Surgical procedure: A prior marking was made on both sides of the LIMA and its veins with bi-polar technique. Hereafter the LIMA and its veins were dissected free with scissor and forceps. Clips were added to all side branches. When the full length of LIMA was obtained, the LIMA and its veins were divided distally by adding clips on the peripheral part of the vessels and proximately dividing by scissor. A vessel-clamp was placed distally and the pedicled LIMA placed in the jugular cavity with a cloth containing papaverine.

Active Comparator: Surgical skeletonised

Harvesting of LIMA in a "naked" fashion where you dissect the artery free of the surrounding tissue.

Procedure: Surgical skeletonised
Surgical procedure: The fascia of the LIMA was opened with a scissor. Hereafter the LIMA was dissected free with scissor and forceps, clips on all LIMA side-branches and divided by scissor. When the full length of LIMA was obtained, the LIMA was divided distally by adding clips on the peripheral part of the vessel and proximately dividing by scissor. A vessel-clamp was placed distally, and the skeletonised LIMA placed in the jugular cavity with a cloth containing papaverine.

Active Comparator: Skeletonised with Thunderbeat

Same as Surgical skeletonised but instead of closing the side branches with clips a surgical tool is used for coagulation of the side-branches.

Procedure: Thunderbeat skeletonised
Surgical procedure: With Thunderbeat the fascia of LIMA was opened. The LIMA was dissected free with Thunderbeat including all side-branches. When the full length of the LIMA was obtained, the LIMA was divided distally by adding clips on the peripheral part of the vessel and proximately dividing by scissor. A vessel-clamp was placed distally, and the skeletonised LIMA placed in the jugular cavity with a cloth containing papaverine.

Outcome Measures

Primary Outcome Measures

  1. Differences in flow in LIMA and pulssatility index between the three groups. [Perioperative - After weaning off the extracorporeal circulation just before closing the thorax]

    mL/ min With transit time flowmetry (Sono TT flowlab), the graft flow and peripheral index (PI) are measured after weaning off the extracorporeal circulation with a systolic pressure aimed at 100 mmHg. The measurements are done with probe size 3 or 4.

Secondary Outcome Measures

  1. Postoperative bleeding [Postoperative bleeding is measured from the end of the operation to removal of the mediastinal drains in the intensive care unit]

    Unit: mL

  2. Re-operation due to bleeding [Up to 48 hours calculated from the end of primaery surgery]

    Number of patients in each group

  3. Re-operation due to ischemia [Up to 48 hours calculated from the end of primaery surgery]

    Number of patients in each group

  4. Pleurocentesis [Up to 10 days calculated from the end of primaery surgery]

    Number of patients in each group

  5. Myocardial injury - creatine kinase-MB (CK-MB) [Routine bloodsample measured four hours after aortic cross clamp removal.]

    Unit: (µg/L)

  6. Myocardial injury - cardiac troponin (cTn) [Routine bloodsample measured four hours after aortic cross clamp removal.]

    Unit: (ng/L)

  7. Differences in pre and post operative regional oxygen saturation on the thorax. [Measured 7 days prior to surgery and again 3 days after surgery]

    Unit: oxygen saturation (rSO2)

  8. Length of stay on ICU [Day of surgery to the day of discharge from ICU. Up to 52 weeks]

    Unit: Days

  9. Length of stay in hospital [Day of surgery to the day of discharge from hospital. Up to 52 weeks]

    Unit: Days

  10. EQ-5D-5L questionnaire: differences in self reported assessment of patient quality of life between the 3 groups [Questionnaires uptained the week before the date of surgery and again 3, 30, and 180 days after surgery.]

    Developed by the EURO-QoF group in 1990 to describe five dimensions of quality of life: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has five levels: no problems, slight problems, moderate problems, severe problems and extreme problems and a visual analogue scale recording the patient's self-rated health.

  11. Telephone interview - Questions regarding pain, numbness and wound healing around the thoracic incision. [180 ± 7 days calculated from the date of surgery.]

    All questions are closed questions and qualitative variables (yes/no)

  12. Rate of readmission to hospital due to Major adverse cardiac and cerebrovascular events (MACCE) - early [Early (≤30 days)]

    Number of deaths in each group

  13. Rate of readmission to hospital due to Major adverse cardiac and cerebrovascular events (MACCE) - Intermediate [Intermediate (≤180 days)]

    Number of deaths in each group

  14. Rate of readmission to hospital due to Major adverse cardiac and cerebrovascular events (MACCE) - Long [Long (≤2 years)]

    Number of deaths in each group

  15. Rate of mortality due to cardiac event - Early [Early (≤30 days)]

    Number of deaths in each group

  16. Rate of mortality due to cardiac event - Intermediate [Intermediate (≤180 days)]

    Number of deaths in each group

  17. Rate of mortality due to cardiac event - Iong [Long (≤2 years)]

    Number of deaths in each group

  18. Rate of all-cause mortality - Early [Early (≤30 days)]

    Number of deaths in each group

  19. Rate of all-cause mortality - Intermediate [Intermediate (≤180 days)]

    Number of deaths in each group

  20. Rate of all-cause mortality - long [Long (≤ 2 years)]

    Number of deaths in each group

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Stand-alone CABG (surgical removal of the left atrial appendage (LAAX) is accepted, since it doesn't affect the graft area)

  • On-pump with cardioplegia (otherwise one cannot be sure of the pressure and perfusion during surgery of the graft)

  • Patients aged >18

  • Elective surgery (there is a known higher risk of postoperative complications with urgent surgery)

Exclusion Criteria:
  • CABG combined with other heart surgery, except from LAAX

  • Previous heart surgery

  • LVEF < 40% (there is a known higher risk of postoperative complications with low LVEF)

  • Known cancers (there is a known higher risk of postoperative complication)

  • Thoracic radiation therapy (there is a known higher risk of postoperative complication)

  • Severe chronic obstructive pulmonary disease (COPD) (there is a known higher risk of postoperative complication)

  • Patients not able to understand written consent

  • Urgent and emergent surgery (there is a known higher risk of postoperative complication)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Cardio, Vascular and Thoracic Surgery Odense Region Of Southern Denmark Denmark 5000

Sponsors and Collaborators

  • Lars Peter Riber
  • Odense Patient Data Explorative Network
  • GCP-unit at Odense University Hospital

Investigators

  • Study Director: Lars P Riber, MD, Ph.D. DMSc, Odense University Hospital

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

Responsible Party:
Lars Peter Riber, MD, Associate Professor, Ph.D., DMSc, Odense University Hospital
ClinicalTrials.gov Identifier:
NCT05562908
Other Study ID Numbers:
  • OP_764
  • S-20180083
First Posted:
Oct 3, 2022
Last Update Posted:
Oct 5, 2022
Last Verified:
Oct 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Lars Peter Riber, MD, Associate Professor, Ph.D., DMSc, Odense University Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 5, 2022